FDA Emergency Use Authorization and Scope

The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) on August 7, 2026, for CLiK Extra (dicylanil) from Elanco Animal Health Incorporated (ELAN) for the prevention of New World screwworm (NWS). This authorization applies to sheep, goats, cattle, and pigs and represents an expedited regulatory pathway with less stringent requirements than a full new drug approval. This action follows the U.S. Department of Health and Human Services' declaration of a public health emergency related to NWS on August 18, 2025, and is part of a broader effort by the FDA to rapidly expand the availability of animal drugs.

Mechanism of Action and Product Status

CLiK Extra is a topical suspension containing 65 mg/mL of dicylanil and belongs to the class of Insect Growth Regulators (IGRs). Its target is the molting and cuticle formation of fly larvae, which disrupts larval development and prevents myiasis. The product is already marketed in the United Kingdom and Australia as a preventative treatment for blowfly strike in sheep, with the Australian label indicating up to 29 weeks of protection against Lucilia cuprina, a dicylanil-sensitive species, after a single application. In the United States, it is being made available through the animal drug EUA pathway rather than the traditional Phase 1, 2, and 3 clinical trial system, which allows for the application of existing commercial experience to address the current outbreak.

Demand and Economic Impact

NWS larvae feed on living tissue in the wounds of warm-blooded animals, leading to reduced productivity and mortality. The U.S. Department of Agriculture (USDA) estimates that an NWS outbreak at the level seen in Texas in 1976 would result in producer losses of $561.1 million and total economic losses for the state of $1.4 billion in 2016 dollars. Therefore, the economic value of this EUA extends beyond the revenue generated by the product itself and includes the reduction in livestock losses, the deployment of control personnel, and the mitigation of trade disruptions and movement restrictions. In an environment where the risk of NWS re-emergence is a reality, a readily applicable preventative treatment can complement sterile insect technique (SIT).

Competitive Landscape and Differentiation

Direct competitors include Dectomax-CA1 (doramectin; a glutamate-gated chloride channel agonist) from Zoetis (ZTS), Ivomec (ivermectin; a glutamate-gated chloride channel agonist) from Boehringer Ingelheim, and Exzolt Cattle-CA1 (fluralaner; a GABA-gated chloride channel and glutamate-gated chloride channel inhibitor) from Merck & Co. (MRK). Negasunt Powder, a combination of coumaphos, propoxur, and sulfanilamide, is a topical product used for both prevention and treatment. CLiK Extra differentiates itself by being a topical IGR that inhibits larval development, unlike injectable macrocyclic lactones or broad-spectrum insecticides, thereby broadening the preventative portfolio.

Investment Perspective

This action is a regulatory event that allows for the emergency use of the product in the United States, rather than a full approval or grant of exclusivity. While Elanco has the opportunity to expand its existing product into the U.S. market and collect data on its use in different animal species, the FDA has already authorized several competing products through conditional approval or EUA, which limits the pricing power of any single product. The long-term value for the company will depend on the conversion to a full New Animal Drug Application (NADA), the establishment of supply contracts, and the expansion of the product's use to other animal species, rather than short-term sales.